Get Premium to unlock powerful stock data

Octagon Capital Advisors LP Buys Apellis Pharmaceuticals Inc, Celldex Therapeutics Inc, Cytek Biosciences Inc, Sells Zai Lab, Acceleron Pharma Inc, Curis Inc

Author's Avatar
insider
Nov 16, 2021
Article's Main Image
Investment company Octagon Capital Advisors LP (Current Portfolio) buys Apellis Pharmaceuticals Inc, Celldex Therapeutics Inc, Cytek Biosciences Inc, BridgeBio Pharma Inc, Arcus Biosciences Inc, sells Zai Lab, Acceleron Pharma Inc, Curis Inc, Taysha Gene Therapies Inc, Vera Therapeutics Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Octagon Capital Advisors LP. As of 2021Q3, Octagon Capital Advisors LP owns 30 stocks with a total value of $406 million. These are the details of the buys and sells.

For the details of Octagon Capital Advisors LP's stock buys and sells, go to https://www.gurufocus.com/guru/octagon+capital+advisors+lp/current-portfolio/portfolio

These are the top 5 holdings of Octagon Capital Advisors LP
  1. I-MAB (IMAB) - 764,461 shares, 13.64% of the total portfolio. Shares reduced by 18.95%
  2. Apellis Pharmaceuticals Inc (APLS) - 1,595,911 shares, 12.95% of the total portfolio. Shares added by 27.04%
  3. Celldex Therapeutics Inc (CLDX) - 761,398 shares, 10.12% of the total portfolio. Shares added by 35.63%
  4. Arcus Biosciences Inc (RCUS) - 970,164 shares, 8.33% of the total portfolio. Shares added by 27.63%
  5. BridgeBio Pharma Inc (BBIO) - 569,414 shares, 6.57% of the total portfolio. Shares added by 49.48%
New Purchase: Cytek Biosciences Inc (CTKB)

Octagon Capital Advisors LP initiated holding in Cytek Biosciences Inc. The purchase prices were between $17.52 and $27.93, with an estimated average price of $23.54. The stock is now traded at around $22.845000. The impact to a portfolio due to this purchase was 2.64%. The holding were 500,000 shares as of 2021-09-30.

New Purchase: Omega Therapeutics Inc (OMGA)

Octagon Capital Advisors LP initiated holding in Omega Therapeutics Inc. The purchase prices were between $16 and $22.51, with an estimated average price of $19.2. The stock is now traded at around $19.680000. The impact to a portfolio due to this purchase was 1.72%. The holding were 370,279 shares as of 2021-09-30.

New Purchase: Tenax Therapeutics Inc (TENX)

Octagon Capital Advisors LP initiated holding in Tenax Therapeutics Inc. The purchase prices were between $1.23 and $2.07, with an estimated average price of $1.64. The stock is now traded at around $1.389900. The impact to a portfolio due to this purchase was 0.01%. The holding were 30,600 shares as of 2021-09-30.

Added: Apellis Pharmaceuticals Inc (APLS)

Octagon Capital Advisors LP added to a holding in Apellis Pharmaceuticals Inc by 27.04%. The purchase prices were between $31.4 and $69.84, with an estimated average price of $56.51. The stock is now traded at around $45.020000. The impact to a portfolio due to this purchase was 2.76%. The holding were 1,595,911 shares as of 2021-09-30.

Added: Celldex Therapeutics Inc (CLDX)

Octagon Capital Advisors LP added to a holding in Celldex Therapeutics Inc by 35.63%. The purchase prices were between $28.95 and $55.99, with an estimated average price of $46.84. The stock is now traded at around $43.520000. The impact to a portfolio due to this purchase was 2.66%. The holding were 761,398 shares as of 2021-09-30.

Added: BridgeBio Pharma Inc (BBIO)

Octagon Capital Advisors LP added to a holding in BridgeBio Pharma Inc by 49.48%. The purchase prices were between $46.87 and $64.24, with an estimated average price of $53.73. The stock is now traded at around $48.220000. The impact to a portfolio due to this purchase was 2.17%. The holding were 569,414 shares as of 2021-09-30.

Added: Arcus Biosciences Inc (RCUS)

Octagon Capital Advisors LP added to a holding in Arcus Biosciences Inc by 27.63%. The purchase prices were between $26.93 and $37.68, with an estimated average price of $31.1. The stock is now traded at around $38.020000. The impact to a portfolio due to this purchase was 1.8%. The holding were 970,164 shares as of 2021-09-30.

Added: Century Therapeutics Inc (IPSC)

Octagon Capital Advisors LP added to a holding in Century Therapeutics Inc by 49.34%. The purchase prices were between $20.8 and $31.93, with an estimated average price of $27.1. The stock is now traded at around $20.930000. The impact to a portfolio due to this purchase was 1.23%. The holding were 602,623 shares as of 2021-09-30.

Sold Out: Zai Lab Ltd (ZLAB)

Octagon Capital Advisors LP sold out a holding in Zai Lab Ltd. The sale prices were between $105 and $178.37, with an estimated average price of $144.08.

Sold Out: Acceleron Pharma Inc (XLRN)

Octagon Capital Advisors LP sold out a holding in Acceleron Pharma Inc. The sale prices were between $115.25 and $182.78, with an estimated average price of $130.74.

Sold Out: Taysha Gene Therapies Inc (TSHA)

Octagon Capital Advisors LP sold out a holding in Taysha Gene Therapies Inc. The sale prices were between $15.82 and $21.57, with an estimated average price of $19.03.

Sold Out: Kymera Therapeutics Inc (KYMR)

Octagon Capital Advisors LP sold out a holding in Kymera Therapeutics Inc. The sale prices were between $47.8 and $66.66, with an estimated average price of $57.98.

Sold Out: Merus NV (MRUS)

Octagon Capital Advisors LP sold out a holding in Merus NV. The sale prices were between $16.48 and $27.23, with an estimated average price of $21.52.

Sold Out: Revolution Medicines Inc (RVMD)

Octagon Capital Advisors LP sold out a holding in Revolution Medicines Inc. The sale prices were between $23.95 and $33.41, with an estimated average price of $29.16.



Here is the complete portfolio of Octagon Capital Advisors LP. Also check out:

1. Octagon Capital Advisors LP's Undervalued Stocks
2. Octagon Capital Advisors LP's Top Growth Companies, and
3. Octagon Capital Advisors LP's High Yield stocks
4. Stocks that Octagon Capital Advisors LP keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus